Related Experiment Videos

[Patent ductus arteriosus. A common clinical problem in extremely premature infants]

A K Edstedt-Bonamy1, S Johansson, J Milerad

  • 1Länssjukhuset Gävle-Sandviken.

Lakartidningen
|February 24, 2001
PubMed

Insights

Symptomatic patent ductus arteriosus (PDA) affected nearly half of preterm infants studied. Treatment increasingly involved active therapies like indomethacin or surgery, associated with low birthweight, sepsis, and ventilation needs.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Clinical Pediatrics

Context:

  • Focuses on symptomatic patent ductus arteriosus (PDA) in preterm infants within a level three intensive care unit.
  • Analyzes treatment regimens and incidence from 1997-1999, a period of evolving therapeutic approaches.
  • Examines 95 preterm infants, with 47 (49%) diagnosed with PDA.

Purpose:

  • To investigate the incidence and evolving treatment strategies for symptomatic PDA in a neonatal intensive care setting.
  • To identify factors associated with the presence of PDA in preterm infants.

Summary:

  • Conservative management (fluid restriction, diuretics) was used in 17 infants.
  • Active therapies, including indomethacin (13 infants) and surgical ligation (10 infants), were employed. Seven infants received a combination of indomethacin and surgery.
  • The utilization of active therapies (indomethacin and/or surgery) increased significantly from 50% in 1997 to 85% in 1999.
  • Low birthweight, septicemia, and the need for mechanical ventilation were independently associated with PDA.

Impact:

  • Highlights a trend towards more aggressive treatment for symptomatic PDA in preterm neonates.
  • Identifies key risk factors (low birthweight, sepsis, mechanical ventilation) that warrant close monitoring in preterm infants.
  • Provides insights into clinical decision-making and therapeutic shifts in neonatal intensive care over a defined period.

Related Concept Videos